Angiotensin-Converting Enzyme Inhibitors in Hypertension

Angiotensin converting enzyme inhibitors and pulmonary hypertension.

AIM To evaluate the efficacy of angiotensin converting enzyme inhibitors Enalapril, Fosonopril and Moexipril on mean and systolic pulmonary artery pressure. MATERIAL AND METHODS The study included Ill patients with chronic obstructive bronchopneumopathies associated with arterial hypertension and mild to moderate heart failure (NYHA I-II class). The patients were examined at baseline and afte...

Angiotensin Converting Enzyme in Sarcoidosis

Angiotensin converting enzyme inhibitors.

The purpose of this brief review is to separate the characteristic properties and side effects attributable to the pharmacology of the whole class of angiotensin converting enzyme (ACE) inhibitors from those attributable to the chemical structure and kinetics of each particular ACE inhibitor. The former would be predictable and probably similar for all agents and, therefore, would be expected t...

Angiotensin-converting enzyme inhibitors.

ACE inhibitors have achieved widespread usage in the treatment of cardiovascular and renal disease. ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive, and hypertrophic properties of angiotensin II (Ang II) and the vasodilatory and natriuretic properties of bradykinin and alter the metabolism of a number of other vasoactive substances. ACE inhibitors differ in the che...

Angiotensin converting enzyme inhibitors in the treatment of hypertension

Angiotensin converting enzyme (ACE) catalyses the conversion of angiotensin I (Ang I) to angiotensin II (Ang II). The ACE activity directly related to hypertension as Ang II is the blood pressure regulating hormone. Therefore, ACE inhibitors are a major class of antihypertensive drugs. Captopril, chemical name, was the first orally active ACE inhibitory antihypertensive drug, discovered in 1977...